BioArctic AB

Detailed Description

BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops ABBV-0805, an alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. It also has a joint research agreement with Alligator Bioscience AB (publ) to employ its proprietary antibody generation technologies for developing new product candidates. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.